

## Development Pipeline as at 30 June 2013

### Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Cardiovascular</b>								
<i>Axanum</i> ***	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer in high risk CV patients	III		Withdrawn	Launched		
<i>Brilinta/ Brilique</i> EUCLID	ADP receptor antagonist	outcomes study in patients with PAD	III	4Q 2012	2016	2016	2016	2017
<i>Brilinta / Brilique</i> PEGASUS-TIMI 54	ADP receptor antagonist	outcomes study in patients with prior MI	III	4Q 2010	2015	2015	2015	2017
<i>Bydureon</i> EXSCEL#	GLP-1 receptor agonist	outcomes study	III	2Q 2010	2018	2018	2018	
<i>Bydureon Dual Chamber Pen</i> #	GLP-1 receptor agonist	diabetes	III		3Q 2013	4Q 2013		
<i>Forxiga</i> (dapagliflozin)/ <i>metformin</i> FDC#	SGLT2 inhibitor + metformin FDC	diabetes	III	3Q 2007	4Q 2013	Filed		
<i>Forxiga</i> (dapagliflozin)#	SGLT2 inhibitor	diabetes – add on to DPP-4	III	1Q 2010		Filed		
<i>Forxiga</i> (dapagliflozin)#	SGLT2 inhibitor	diabetes – add on to insulin and add-on to metformin long-term data	III	2Q 2008		Filed		
<i>Forxiga</i> (dapagliflozin)#	SGLT2 inhibitor	diabetes – in patients with high CV risk - Study 18 and 19 long-term data	III	1Q 2010		1H 2014		
<i>Forxiga</i> (dapagliflozin)#	SGLT2 inhibitor	diabetes – triple therapy (dapa+met+SU)	III	1Q 2011		4Q 2013		
<i>Forxiga</i> (dapagliflozin) DECLARE#	SGLT2 inhibitor	outcomes study	III	2Q 2013	2020	2020		
<i>Kombiglyze XR/ Komboglyze</i> FDC#*	DPP-4 inhibitor + metformin FDC	diabetes	III		Launched	Launched		1H 2014
<i>SaxaDapa</i> FDC#	DPP-4 inhibitor / SGLT2 inhibitor	diabetes	III	2Q 2012	2015	2015		
<i>Onglyza</i> SAVOR-TIMI 53#	DPP-4 inhibitor	outcomes study	III	2Q 2010	4Q 2013	4Q 2013		2H 2014

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Gastrointestinal</b>								
<i>Entocort</i>	glucocorticoid steroid	Crohn's disease / ulcerative colitis	III		Launched	Launched	2015	N/A
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III		Filed**	Launched	N/A	Launched
<b>Neuroscience</b>								
<i>Diprivan</i> <sup>#</sup>	sedative and anaesthetic	conscious sedation	III			Launched	2H 2014	Launched
<b>Oncology</b>								
<i>Faslodex</i>	oestrogen receptor antagonist	1 <sup>st</sup> line advanced breast cancer	III	4Q 2012	2016	2016	2016	2016
<i>Iressa</i>	EGFR tyrosine kinase inhibitor	treatment beyond progression	III	1Q 2012		2015	2015	2015
<b>Respiratory, Inflammation &amp; Autoimmunity</b>								
<i>Symbicort</i>	inhaled steroid/ long-acting $\beta_2$ agonist	Breath Actuated Inhaler asthma / COPD	III	4Q 2011	1H 2014			

<sup>#</sup>Partnered product

\*Kombiglyze XR US; Komboglyze FDC EU

\*\*2<sup>nd</sup> CRL received from FDA in 2011. AZ response submitted to FDA in December 2012

\*\*\*Commercial support now withdrawn, no Japan launch expected

**NCEs**  
**Phase III/Registration**

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Cardiovascular</b>								
<i>Brilinta/ Brilique</i>	ADP receptor antagonist	arterial thrombosis	III		Launched	Launched	Filed	Launched
<i>Epanova</i> <sup>#</sup>	omega-3 free fatty acids	hypertriglyceridaemia	III		Filed			
<i>Forxiga (dapagliflozin)</i> <sup>#</sup>	SGLT2 inhibitor	diabetes	III		Filed*	Launched	Filed	Filed
metreleptin <sup>#</sup>	leptin analogue	lipodystrophy	III		Filed	1H 2014	N/A	
<b>Infection</b>								
CAZ AVI <sup>#</sup> (CAZ104)	beta lactamase inhibitor/ cephalosporin	intra abdominal infections (cIAI) & urinary tract infections (cUTI); hospital acquired pneumonia (HAP) & ventilator associated pneumonia (VAP) ***	III	1Q 2012	N/A	2H 2014	2015	2016
Q-LAIV Flu Vaccination**	live, attenuated, intranasal influenza virus vaccine quadrivalent	seasonal influenza	III		Approved	Filed		
<i>Zinforo (ceftaroline)</i> <sup>#</sup>	extended spectrum cephalosporin with affinity to penicillin-binding proteins	pneumonia / skin infections	III		N/A	Launched		1H 2014
<b>Neuroscience</b>								
naloxegol (NKTR-118) <sup>#</sup>	oral peripherally-acting mu-opioid receptor antagonist	opioid-induced constipation	III	2Q 2011	3Q 2013	3Q 2013		
<b>Oncology</b>								
<i>Caprelsa</i>	VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III		Launched	Launched	2015	Filed
moxetumomab pasudotox <sup>#</sup>	anti-CD22 recombinant immunotoxin	hairy cell leukaemia	III	2Q 2013	2017	2017		

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Respiratory, Inflammation &amp; Autoimmunity</b>								
brodalumab <sup>#</sup>	anti-IL-17R MAb	psoriasis	III	3Q 2012	2015	2015		
PT003 GFF	LABA/LAMA	COPD	III	2Q 2013	2015	2016		
lesinurad	selective uric acid reabsorption inhibitor (SURI)	chronic treatment of patients with gout	III	4Q 2011	2H 2014	2H 2014	2017	2017

<sup>#</sup>Partnered product

\*CRL received in January 2012, re-submission 3Q 2013

\*\*sBLA in US, MAA in EU

\*\*\*HAP/VAP is a follow up filing, EU filing expected in 2017

**NCEs**  
**Phases I and II**

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Cardiovascular</b>								
AZD1722 <sup>#</sup>	NHE3 inhibitor	end stage renal disease / chronic kidney disorder	II	1Q 2013				
MEDI6012 (ACP-501)	LCAT	ACS	I	1Q 2012				
<b>Infection</b>								
AZD5847	oxazolidinone anti-bacterial inhibitor	tuberculosis	II	4Q 2012				
CXL <sup>#</sup>	beta lactamase inhibitor/ cephalosporin	MRSA	II	4Q 2010				
ATM AVI	BL/BLI	targeted serious bacterial infections	I	4Q 2012				
MEDI4893	staph alpha toxin YTE MAb	hospital-acquired pneumonia / serious <i>S. aureus</i> infection	I	1Q 2013				
MEDI-550	pandemic influenza virus vaccine	pandemic influenza prophylaxis	I	2Q 2006				
PRVV (MEDI-559)	live attenuated paediatric RSV vaccine	RSV prophylaxis	I	4Q 2008				
<b>Neuroscience</b>								
AZD3241	myeloper-oxidase (MPO) inhibitor	Parkinson's disease	II	2Q 2012				
AZD5213	histamine-3 receptor antagonist	neuropathic pain <sup>*</sup>	II					
AZD6765	NMDA receptor antagonist	major depressive disorder	II	3Q 2007				
AZD3293 <sup>#</sup>	beta secretase	Alzheimer's disease	I	4Q 2012				

<sup>#</sup>Partnered product

<sup>\*</sup>Terminated in Alzheimer's Disease – neuropathic pain study due to start 3Q 2013

**NCEs**  
***Phases I and II (continued)***

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Oncology</b>								
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	II	4Q 2011				
MEDI-551 <sup>#</sup>	anti-CD19 MAb	haematological malignancies	II	1Q 2012				
MEDI-573 <sup>#</sup>	anti-IGF MAb	MBC	II	4Q 2011				
olaparib	PARP inhibitor	gBRCAm ovarian cancer, gBRCAm breast cancer, gastric cancer	II	1Q 2012				
selumetinib <sup>#</sup> (AZD6244) (ARRY-142886)	MEK inhibitor	solid tumours	II	4Q 2006				
tremelimumab	anti-CTLA4 MAb	solid tumours	II	3Q 2004				
AZD1208	PIM kinase inhibitor	haematological malignancies	I	1Q 2012				
AZD2014	TOR kinase inhibitor	solid tumours	I	1Q 2010				
AZD5363 <sup>#</sup>	AKT inhibitor	solid tumours	I	4Q 2010				
AZD8186	PI3 kinase beta inhibitor	solid tumours	I	2Q 2013				
AZD9150 <sup>#</sup>	STAT3 inhibitor	haematological malignancies	I	1Q 2012				
AZD9291	epidermal growth factor inhibitor	solid tumours	I	1Q 2013				
MEDI0639 <sup>#</sup>	anti-DLL-4 MAb	solid tumours	I	2Q 2012				
MEDI3617 <sup>#</sup>	anti-ANG-2 MAb	solid tumours	I	4Q 2010				
MEDI4736 <sup>#</sup>	anti-PD-L1 MAb	solid tumours	I	3Q 2012				
MEDI-565 <sup>#</sup>	anti-CEA BiTE	solid tumours	I	1Q 2011				
MEDI6469 <sup>#</sup>	murine anti-OX40 MAb	solid tumours	I	1Q 2006				
volitinib <sup>#</sup>	MET inhibitor	solid tumours	I	1Q 2012				

<sup>#</sup>Partnered product

**NCEs**  
***Phases I and II (continued)***

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	China
<b>Respiratory, Inflammation &amp; Autoimmunity</b>								
AZD2115 <sup>#</sup>	MABA	COPD	II	2Q 2012				
AZD5069	CXCR2	asthma	II	4Q 2010				
AZD5423 <sup>#</sup>	inhaled SGRM	COPD	II	4Q 2010				
benralizumab <sup>#</sup>	anti-IL-5R MAb	asthma / COPD	II	4Q 2008				
mavrilimumab <sup>#</sup>	anti-GM-CSFR MAb	rheumatoid arthritis	II	1Q 2010				
MEDI2070 <sup>#</sup>	anti-IL-23 MAb	Crohn's disease	II	1Q 2013				
MEDI-546 <sup>#</sup>	anti-IFN-alphaR MAb	SLE	II	1Q 2012				
MEDI7183 <sup>#</sup>	anti-a4b7 MAb	Crohn's disease / ulcerative colitis	II	4Q 2012				
MEDI8968 <sup>#</sup>	anti-IL-1R MAb	COPD, HS	II	4Q 2011				
sifalimumab <sup>#</sup>	anti-IFN-alpha MAb	SLE	II	3Q 2008				
tralokinumab	anti-IL-13 MAb	asthma / IPF / UC	II	1Q 2008				
AZD8848 <sup>#</sup>	inhaled TLR7	asthma	I	2Q 2012				
AZD7594 <sup>#</sup>	inhaled SGRM	COPD	I	4Q 2012				
AZD7624	ip38i	COPD	I	1Q 2013				
MEDI-551 <sup>#</sup>	anti-CD19 MAb	multiple sclerosis	I	3Q 2012				
MEDI5872 <sup>#</sup>	anti-B7RP1 MAb	SLE	I	4Q 2008				
MEDI9929 <sup>#</sup>	anti-TSLP MAb	asthma	I	4Q 2008				
RDEA3170	selective uric acid reabsorption inhibitor (SURI)	chronic treatment of patients with gout	I	3Q 2011				

<sup>#</sup>Partnered product

## Development Pipeline - Discontinued Projects between 1 January 2013 and 30 June 2013

### Infection

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	MEDI-557	safety / efficacy	RSV prevention in high risk adults (COPD/CHF/other)

### Neuroscience

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD1446	safety / efficacy	Alzheimer's disease
NCE	AZD3480	safety / efficacy	Alzheimer's disease
NCE	MEDI15117	safety / efficacy	rheumatoid arthritis

### Oncology

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD8330 <sup>#</sup> (ARRY 424704)	safety / efficacy	solid tumours
NCE	fostamatinib	safety / efficacy	haematological malignancies
NCE	MEDI-575	safety / efficacy	NSCLC

### Respiratory, Inflammation & Autoimmunity

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	fostamatinib	safety / efficacy	rheumatoid arthritis
NCE	MEDI7814	economic	COPD
NCE	MEDI4212	safety / efficacy	asthma

### Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Submission dates shown for assets in Phase III and beyond.